Accenture invests in Iridius, terms not disclosed

Accenture (ACN) has invested, through Accenture Ventures, in Iridius, an enterprise AI infrastructure company that designs compliant-by-design AI solutions for highly regulated industries, including life sciences and pharmaceuticals sectors. The company said, “As part of this investment, Accenture and Iridius will also form a strategic partnership to support life sciences organizations in scaling AI adoption while ensuring compliance, traceability, and auditability are integrated at every stage. The collaboration will combine Accenture’s deep industry knowledge and delivery scale with AI-powered regulatory and compliance capabilities from Iridius, enabling clients to move beyond isolated AI pilots and achieve enterprise-wide, compliant AI transformation. Together, Accenture and Iridius will build end-to-end compliance workflows across the life sciences value chain, from regulatory submissions and pharmacovigilance to clinical and manufacturing operations. This will help speed up regulatory and clinical timelines, reduce manual compliance work, and maintain ongoing audit readiness.” Terms of the investment were not disclosed.